Abstract
The degradation kinetics of 5 × 10−5 M cyanocobalamin (B12) and hydroxocobalamin (B12b) in the presence of ascorbic acid (AH2) was studied in the pH range of 1.0–8.0. B12 is degraded to B12b which undergoes oxidation to corrin ring cleavage products. B12b alone is directly oxidized to the ring cleavage products. B12 and B12b in degraded solutions were simultaneously assayed by a two-component spectrometric method at 525 and 550 nm without interference from AH2. Both degrade by first-order kinetics and the values of the rate constants at pH 1.0–8.0 range from 0.08 to 1.05 × 10−5 s−1 and 0.22–7.62 × 10−5 s−1, respectively, in the presence of 0.25 × 10−3 M AH2. The t1/2 values of B12 and B12b range from 13.7 to 137.5 h and 2.5–87.5 h, respectively. The second-order rate constants for the interaction of AH2 with B12 and B12b are 0.05–0.28 × 10−2 and 1.10–30.08 × 10−2 M−1 s−1, respectively, indicating a greater effect of AH2 on B12b compared to that of B12. The kobs–pH profiles for both B12 and B12b show the highest rates of degradation around pH 5. The degradation of B12 and B12b by AH2 is affected by the catalytic effect of phosphate ions on the oxidation of AH2 in the pH range 6.0–8.0.
KEY WORDS: ascorbic acid, cyanocobalamin, degradation, hydroxocobalamin, kinetics, two-component spectrometry
INTRODUCTION
Cyanocobalamin (vitamin B12) (B12) and hydroxocobalamin (vitamin B12b) (B12b) were originally isolated from liver fractions and Streptomyces griseus (1,2). These vitamins are complex organometallic cofactors associated with cobalamin-dependent enzymes that are involved in different catalytic functions in bacteria and humans (3). B12 deficiency produces profound pathological effects on the blood, nervous system, and other organs. The most prominent effect of B12 deficiency is megaloblastic anemia that is caused by the disruption of DNA synthesis (4). B12 [α-(5,6-dimethyl-bezimidazol-1-yl)cobamide cyanide] and B12b [Coα-[α-(5,6-dimethylbezimidazolyl)]-Coβ-hydroxocobamide] (5) are chemically related (Fig. 1). The CN group attached to Co3+ in the tetrapyrrolic corrin macrocyclic ring in B12 is replaced by an OH group in B12b. B12 undergoes photolysis to B12b in aqueous solution which is degraded to irreversible oxidation products (6–11). Similar reactions occur on the chemical degradation of B12 and B12b in the presence of ascorbic acid (AH2) (12–14) and may be expressed as follows:
![]() |
1 |
![]() |
2 |
Fig. 1.

Chemical structures of a cyanocobalamin (B12), b hydroxocobalamin (B12b), c Cob(II)alamin (B12r), d ascorbic acid (AH2), and e dehydroascorbic acid (A)
The effect of thiamine (15,16), nicotinamide (17,18), and riboflavin (19–22) on the photolysis of B12 and B12b has been investigated. Several studies have been conducted on the incompatibility and interaction of B12 and AH2 that lead to the loss of B12 in aqueous solution (12,13,23–27). B12b has been found to be less stable than B12 in the presence of AH2 (28–30) and is destroyed to form unknown oxidation products (9,12,31,32). 3,3-Dimethyl-2,5-dioxopyrrolidine-4-propionamide and 3,3-dimethyl-2,5-dioxopyrrolidine-4-propionic acid have been identified as the oxidation products of B12 (33). The chemical (34–36) and photodegradation (21,37) of B12 and B12b has been reported to follow first-order kinetics.
The early studies on the stability and degradation of B12 and B12b are largely qualitative and no systematic work on the kinetics of degradation of these vitamins in the presence of other vitamins has been carried out. One of the reasons for this approach has been the nonavailability of specific methods for the simultaneous assay of B12 and B12b in degraded solutions (10,18,19). In view of the occurrence of vitamins as mixtures in pharmaceutical preparations, there is a need to reinvestigate their interactions and degradation profiles to achieve greater stability and therapeutic efficacy. B12 and AH2 both are components of liquid vitamin B-complex with vitamin C (AH2) and multivitamin preparations, and B12 is liable to degradation in the presence of AH2 during manufacture, storage, and use. B12b is an intermediate product in the degradation sequence of B12 and, therefore, a study of its degradation behavior is of fundamental importance in understanding the stability characteristics of B12. It is necessary to ascertain the role of AH2 in the degradation of B12 and of its degradation product, B12b, together with that of B12b alone. AH2 is oxidized to dehydroascorbic acid (A) (12,14,38) in these reactions. The present work is based on a kinetic study of the comparison of degradation of B12 and B12b in the presence of AH2 over a wide range of pH (1.0–8.0), that covers the pH range employed for the formulation of vitamin preparations. The study throws light on the interaction of AH2 with B12 and B12b and the extent of formation of oxidation products in these reactions. The magnitude of rate–pH profiles for the degradation of B12 and B12b provides an indication of the degree of interaction of AH2 with B12 and B12b as a function of pH. The mode of degradation of B12 and B12b in the presence of AH2 has also been outlined. The information would be of considerable importance to the chemists and pharmacists in designing vitamin formulations with optimum stability of B12 and B12b. The chemical structures of B12, B12b, B12r, AH2, and A are shown in Fig. 1.
MATERIAL AND METHODS
Materials
B12, B12b, AH2, and A were obtained from Sigma-Aldrich. All reagents and solvents were of the purest form available from BDH and Merck. The following buffer systems were used throughout the work:
-
For degradation reactions:
KCl / HCl (pH 2.0) and citric acid / Na2HPO4 (pH 2.5–8.0); the ionic strength was 0.05 M in each case.
-
For assay:
CH3COOH/CH3COONa, 0.2 M (pH 4.0).
Precautions
The degradation, assay, and thin-layer chromatography of B12b solutions were carried out in a dark chamber under subdued light. The solutions were protected from light during preparation and handling.
Degradation of B12 and B12b
A 5 × 10−5 M aqueous solution of B12 or B12b (100 ml) was prepared at pH 1.0–8.0 using the appropriate buffer, and sufficient amount of AH2 was added to produce dilutions in the range of 0.25–1.50 × 10−3 M (B12) and 0.05–0.25 × 10−3 M (B12b). The solution was placed in a water bath maintained at 25 ± 1°C in the dark chamber to carry out the degradation. The rate of the reaction was followed by spectrometry.
Thin-layer Chromatography
Thin-layer chromatography (TLC) of the solutions of B12 and B12b, degraded in the presence of AH2, was performed on 250-μm silica gel GF254 plates (Merck) using the following solvent systems:
B12 and B12b, (a) 1-butanol/acetic acid/0.066 M KH2PO4/methanol (36:18:36:10, v/v) (39); and (b) methanol/water (95:5, v/v) (40). The spots were located visually (red color).
AH2 and A, (c) acetic acid/acetone/methanol/benzene (5:5:20:70, v/v) (41); and (d) ethanol/10% acetic acid (90:10, v/v) (42). The spots were located under UV (254 nm) excitation (AH2) using a Uvitech lamp (Cambridge, UK), or by spraying with a 3% aqueous phenylhydrazine solution (orange red color) (A).
Spectral Determination
All spectral determinations on B12 and B12b and the degraded solutions were carried out on a Shimadzu UV-1601 recording spectrophotometer using quartz cells of 10-mm path length.
Spectrometric Assay
The assay of B12 and its degradation product, B12b, in degraded solutions in the presence of AH2 was carried out at by a two-component spectrometric method at 525 and 550 nm (pH 4.0, acetate buffer) (10). The degradation products of B12b formed by the breakdown of the corrin ring may absorb in the UV region and do not interfere with the assay method. The method was validated in the presence of the highest concentration of AH2 to ensure their accuracy, reproducibility, and specificity under the experimental conditions used.
RESULTS AND DISCUSSION
Degradation Products of B12, B12b, and AH2
TLC has been applied to detect the products formed on the degradation of B12 and B12b in the presence of AH2. The experimental conditions for the degradation of these vitamins (5 × 10−5 M) at pH 1.0–8.0 involved AH2 concentrations of 0.25–1.5 × 10−3 M (B12) and 0.05–0.25 × 10−3 M (B12b). TLC of the degraded solutions of B12 (Rf 0.46 and 0.42 in solvent systems (a) and (b), respectively) showed the presence of B12b only at all pH values (Rf 0.26 and 0.05 in solvent systems (a) and (b), respectively) whereas no degradation product has been detected in B12b solutions in the pH range studied.
B12 is known to be converted to B12b by reducing agents including AH2 (12–14). B12b is destroyed more rapidly by AH2 than B12, with a loss of color to indicate the release of cobalt from the molecule (24) and formation of the corrin ring cleavage oxidation products (9,13,32). These products could not be identified by TLC in this study. The oxidation products of B12 have been identified as 3,3-dimethyl-2,5-dioxopyrrolidine-4-propionamide and 3,3-dimethyl-2,5-dioxopyrrolidine-4-propionic acid (33). In the acid medium, the breakdown products of B12 include mixtures of carboxylic acid, γ-lactone and 1-amino-2-propanol (9,13), which do not absorb in the visible region. An Rf 0.22 and 0.73 in solvent systems (c) and (d), respectively, has been detected for A as an oxidation product of AH2 (Rf 0.30 and 0.49 in (c) and (d), respectively) in the degraded solutions of B12 and B12b.
Spectral Characteristics and Color Changes of B12 and B12b in Degraded Solutions
B12 and B12b exhibit absorption maxima at 278, 361, and 550 nm and 274, 351, and 525 nm, respectively, in water (5,43). AH2 absorbs at 265 nm at pH 6.4 (44) and does not interfere in the visible region. The absorption spectra of a B12b solution (pH 5.0) stored in the presence of 1 × 10−3 M AH2 in the dark are shown in Fig. 2. A slight increase in absorbance in the 450–500 nm region after about 90 min gives an indication of the presence of the reduced form of B12b (Cob(II)alamin, B12r), absorbing at 474 nm (45). After about 180 min, the spectrum of the colorless solution showed negligible absorption in the visible region as a result of the oxidation of corrin ring (33).
Fig. 2.

Absorption spectra of hydroxocobalamin solution (5 × 10−5 M) stored in the presence of ascorbic acid (1.5 × 10−3 M). a 0 h, red, b 1.5 h, brownish red, c 3 h, colorless
A B12 solution (pH 5.0) stored in the dark in the presence of AH2 became slightly lighter in color and gradually turned reddish brown. This was followed by a change in color to yellow, and ultimately, the solution became colorless. These changes were more rapid in the degraded solution of B12b. The color changes involved in the degradation of B12 have been ascribed to the formation of the reduced form of B12 (B12r) (red to reddish brown), reaction intermediates (brown to yellow) and corrin ring oxidation products (yellow to colorless) (24). In the presence of air B12r is slowly oxidized to B12b (32): similar rapid color changes have been observed in B12b solutions, degraded in the presence of AH2. These changes indicate that B12 undergoes degradation to B12r which may further degrade to colorless oxidation products by the cleavage of the corrin ring or be oxidized to B12b which could also be transformed to the colorless oxidation products in the presence of AH2 (32).
Assay of B12 and B12b in Degraded Solutions
The absorption maxima of B12 and B12b occur at 361 and 550 nm and 351 and 525 nm, respectively, in aqueous solution (43). The British Pharmacopoeia (5) method for the assay of these vitamins is based on the measurement of their absorbance at 361 and 351 nm, respectively. However, due to overlapping of the absorption bands in this region and in the 525 and 550 nm region, the assay of the individual vitamins is not possible. In order to overcome this problem, a two-component spectrometric method was developed and applied to study the kinetics of photolysis of B12 alone (11,19), and also in the presence of nicotinamide (18) and riboflavin (19,20) and the degradation of B12 in parenteral solutions (31). Since B12b is also a product of photolysis of B12, both B12 and B12b can be conveniently assayed by this method in B12 solutions degraded in the presence of AH2. AH2 absorbs at 265 nm (pH 6.4) (44) and does not interfere in the simultaneous assay of B12 and B12b by this method. Since the ultimate degradation of B12 and B12b results in the cleavage of corrin ring to form the oxidation products, which may absorb in the UV region, the set of wavelength 525 and 550 nm in the visible region has been preferred for the two-component assay of B12 and B12b in degraded solutions. B12b has directly been assayed at 525 nm to avoid any interference from degradation products. The assay method has been validated in the presence of AH2 and has a precision of ±2% (Table I). The results of the assay of B12 and B12b in a typical degradation reaction carried out at pH 5.0 are given in Table II. The increasing loss of molar balance for B12 and B12b, with time, is due to the formation of the oxidation products (OP) and is an indication of the destructive effect of AH2 on both B12 and B12b. The gradual decrease in the OP/B12b ratios suggests that B12b may be produced by more than one pathway. This has been discussed under the section on the mode of degradation of B12. Control solution of B12 and B12b kept in the dark in the absence of AH2 did not show any degradation during the period of the reactions.
Table I.
Validation Data (n = 5) for Cyanocobalamin (B12) and Hydroxocobalamin (B12b)
| B12 | B12b | |
|---|---|---|
| Absorption maxima | 550 | 525 |
| Molar absorptivity (M−1 cm−1) | 8.70 × 103 | 8.64 × 103 |
| Linearity range (M × 10−5) | 1.0–5.0 | 1.0–5.0 |
| Correlation coefficient | 0.9998 | 0.9998 |
| Slope | 8700 | 8640 |
| Intercept | −0.0018 | −0.0090 |
| SE (±) of slope | 0.0031 | 0.0040 |
| SE of intercept | 0.0032 | 0.0030 |
| SD of intercept | 0.0073 | 0.0068 |
| Recovery range (%) | 98.79–101.03 | 98.96–101.85 |
| Accuracy (%) ± SD | 100.03 ± 0.865 | 100.19 ± 1.121 |
| % RSD | 0.865 | 1.119 |
| LOD (M × 10−5) | 0.276 | 0.260 |
| LOQ (M × 10−5) | 0.835 | 0.787 |
LOD limit of detection, LOQ limit of quantification
Table II.
Degradation of Cyanocobalamin (B12) in the Presence of Ascorbic acid (AH2) at pH 5.0
| Time (h) | B12 (M × 105) | B12b (M × 105) | B12 + B12b (M × 105) | OPa (M × 105) | OP/B12b |
|---|---|---|---|---|---|
| 0 | 5.00 | – | 5.00 | – | – |
| 2 | 4.68 | 0.20 | 4.88 | 0.12 | 0.60 |
| 4 | 4.25 | 0.47 | 4.72 | 0.28 | 0.60 |
| 6 | 3.85 | 0.73 | 4.58 | 0.42 | 0.58 |
| 8 | 3.54 | 0.95 | 4.49 | 0.51 | 0.53 |
| 10 | 3.25 | 1.21 | 4.46 | 0.54 | 0.45 |
| 12 | 2.96 | 1.47 | 4.43 | 0.57 | 0.39 |
| 14 | 2.70 | 1.69 | 4.39 | 0.61 | 0.36 |
| 16 | 2.46 | 1.90 | 4.36 | 0.64 | 0.34 |
| 20 | 2.13 | 2.19 | 4.32 | 0.68 | 0.31 |
| 24 | 1.77 | 2.52 | 4.29 | 0.71 | 0.28 |
| 28 | 1.47 | 2.79 | 4.46 | 0.74 | 0.26 |
| 32 | 1.24 | 2.98 | 4.22 | 0.76 | 0.25 |
Experimental conditions were as follows: initial concentration of B12, 5 × 10−5 M; concentration of AH2, 1.5 × 10−3 M; degradation time, 32 h; temperature, 25 ± 1°C; storage, in dark
aOxidation products (OP) of B12 = [initial concentration of B12 – (molar concentration of B12 + molar concentration of B12b at various time intervals)]
Kinetics of Degradation of B12 and B12b
B12 is known to degrade to B12b and B12b to irreversible oxidation products in aqueous solution in the presence of AH2. Both reactions are affected by AH2 and the degradation of B12b alone is much faster than B12 in the presence of AH2 as discussed in the above sections. These reactions have been studied at pH 1.0–8.0 to assess the degradation behavior of B12 and B12b. Therefore, the assay data on the degradation of B12 and B12b were subjected to kinetic treatment, and it was found that these vitamins degrade by an apparent first-order kinetics in the presence of AH2. This is in agreement with the previous observations that the chemical degradation of B12 and B12b follows first-order kinetics (34–36). The apparent first-order rate constants (kobs) for the degradation of B12 and B12b are given in Table III and IV, respectively. The values of kobs indicate that the degradation of B12 and B12b is promoted by AH2, and the rate increases with an increase in AH2 concentration throughout the pH range employed. In order to correlate the values of kobs with AH2 concentrations, these values were plotted against the respective AH2 concentrations for the two vitamins and the second-order rate constants (k2) for the interaction of AH2 with B12 and B12b were determined from the slopes of the straight lines (correlation coefficients 0.996–0.999) (Table V). A comparison of the values of k2 for B12 and B12b under the reaction conditions employed shows that the rate of interaction of AH2 with B12b is about 20 (pH 1.0) to 100 (pH 5.0) times faster than that of B12. Earlier studies have shown that the degradation of B12b is faster than B12 in the presence of AH2 (28,46), but no comparison of the kinetic data in these reactions has been made.
Table III.
Apparent First-Order Rate Constants (k obs) for the Degradation of Cyanocobalamin (B12) in the Presence of Ascorbic acid (AH2) at pH 1.0–8.0
| pH | k obs × 105 [s−1] ± SDa | |||||
|---|---|---|---|---|---|---|
| 0.25b | 0.50b | 0.75b | 1.00b | 1.25b | 1.50b | |
| 1.0 | 0.08 ± 0.005 | 0.10 ± 0.006 | 0.11 ± 0.006 | 0.12 ± 0.005 | 0.13 ± 0.007 | 0.14 ± 0.009 |
| 1.5 | 0.10 ± 0.006 | 0.12 ± 0.005 | 0.13 ± 0.007 | 0.15 ± 0.008 | 0.16 ± 0.009 | 0.18 ± 0.008 |
| 2.0 | 0.11 ± 0.006 | 0.14 ± 0.008 | 0.18 ± 0.009 | 0.21 ± 0.009 | 0.23 ± 0.008 | 0.26 ± 0.008 |
| 2.5 | 0.30 ± 0.01 | 0.35 ± 0.02 | 0.38 ± 0.02 | 0.41 ± 0.02 | 0.45 ± 0.03 | 0.50 ± 0.01 |
| 3.0 | 0.49 ± 0.03 | 0.53 ± 0.03 | 0.58 ± 0.04 | 0.63 ± 0.04 | 0.67 ± 0.03 | 0.72 ± 0.03 |
| 3.5 | 0.77 ± 0.04 | 0.82 ± 0.04 | 0.88 ± 0.05 | 0.94 ± 0.04 | 0.99 ± 0.04 | 1.05 ± 0.04 |
| 4.0 | 0.99 ± 0.05 | 1.06 ± 0.05 | 1.12 ± 0.05 | 1.19 ± 0.06 | 1.26 ± 0.07 | 1.32 ± 0.04 |
| 4.5 | 1.02 ± 0.06 | 1.08 ± 0.06 | 1.14 ± 0.06 | 1.21 ± 0.05 | 1.28 ± 0.05 | 1.36 ± 0.07 |
| 5.0 | 1.05 ± 0.05 | 1.12 ± 0.05 | 1.18 ± 0.05 | 1.26 ± 0.06 | 1.33 ± 0.08 | 1.40 ± 0.08 |
| 5.5 | 0.95 ± 0.05 | 1.04 ± 0.05 | 1.11 ± 0.07 | 1.19 ± 0.06 | 1.27 ± 0.05 | 1.33 ± 0.06 |
| 6.0 | 0.91 ± 0.04 | 0.97 ± 0.04 | 1.03 ± 0.05 | 1.10 ± 0.04 | 1.17 ± 0.06 | 1.22 ± 0.05 |
| 6.5 | 0.49 ± 0.02 | 0.53 ± 0.02 | 0.56 ± 0.03 | 0.60 ± 0.03 | 0.64 ± 0.03 | 0.68 ± 0.03 |
| 7.0 | 0.29 ± 0.02 | 0.31 ± 0.02 | 0.34 ± 0.02 | 0.37 ± 0.02 | 0.40 ± 0.02 | 0.43 ± 0.02 |
| 7.5 | 0.16 ± 0.01 | 0.18 ± 0.01 | 0.19 ± 0.01 | 0.20 ± 0.01 | 0.21 ± 0.01 | 0.23 ± 0.01 |
| 8.0 | 0.11 ± 0.01 | 0.12 ± 0.01 | 0.13 ± 0.01 | 0.14 ± 0.01 | 0.15 ± 0.01 | 0.16 ± 0.01 |
Experimental conditions were as follows: initial concentration of B12, 5 × 10−5 M; concentration of AH2, 0.25–1.50 × 10−3 M; degradation time, 15 h; temperature, 25 ± 1°C; storage, in dark
a n = 3
bAH2 concentration (M × 103)
Table IV.
Apparent First-Order Rate Constants (k obs) for the Degradation of Hydroxocobalamin (B12b) in the Presence of Ascorbic acid (AH2) at pH 1.0–8.0
| pH | k obs × 105 [s−1] ± SDa | ||||
|---|---|---|---|---|---|
| 0.05b | 0.10b | 0.15b | 0.20b | 0.25b | |
| 1.0 | 0.04 ± 0.002 | 0.08 ± 0.004 | 0.13 ± 0.006 | 0.17 ± 0.008 | 0.22 ± 0.01 |
| 1.5 | 0.06 ± 0.003 | 0.15 ± 0.005 | 0.23 ± 0.010 | 0.28 ± 0.142 | 0.34 ± 0.02 |
| 2.0 | 0.11 ± 0.01 | 0.28 ± 0.01 | 0.41 ± 0.02 | 0.50 ± 0.03 | 0.64 ± 0.03 |
| 2.5 | 0.17 ± 0.01 | 0.47 ± 0.02 | 0.68 ± 0.03 | 0.80 ± 0.03 | 1.04 ± 0.04 |
| 3.0 | 0.42 ± 0.03 | 0.89 ± 0.04 | 1.40 ± 0.06 | 1.82 ± 0.08 | 2.30 ± 0.09 |
| 3.5 | 0.85 ± 0.03 | 1.76 ± 0.09 | 2.64 ± 0.10 | 3.55 ± 0.14 | 4.47 ± 0.20 |
| 4.0 | 1.24 ± 0.05 | 2.63 ± 0.14 | 4.05 ± 0.16 | 5.37 ± 0.25 | 6.65 ± 0.28 |
| 4.5 | 1.45 ± 0.06 | 2.82 ± 0.11 | 4.25 ± 0.18 | 5.65 ± 0.23 | 7.04 ± 0.32 |
| 5.0 | 1.55 ± 0.06 | 3.04 ± 0.12 | 4.65 ± 0.19 | 6.02 ± 0.29 | 7.62 ± 0.36 |
| 5.5 | 1.42 ± 0.06 | 2.75 ± 0.14 | 4.15 ± 0.17 | 5.48 ± 0.25 | 6.80 ± 0.37 |
| 6.0 | 0.80 ± 0.03 | 1.69 ± 0.07 | 2.54 ± 0.10 | 3.40 ± 0.16 | 4.20 ± 0.22 |
| 6.5 | 0.65 ± 0.03 | 1.30 ± 0.05 | 2.05 ± 0.12 | 2.72 ± 0.12 | 3.45 ± 0.14 |
| 7.0 | 0.52 ± 0.03 | 1.12 ± 0.05 | 1.65 ± 0.07 | 2.24 ± 0.09 | 2.76 ± 0.13 |
| 7.5 | 0.42 ± 0.02 | 0.77 ± 0.04 | 1.21 ± 0.05 | 1.55 ± 0.06 | 2.02 ± 0.08 |
| 8.0 | 0.35 ± 0.02 | 0.63 ± 0.03 | 0.99 ± 0.05 | 1.28 ± 0.06 | 1.60 ± 0.08 |
Experimental conditions were as follows: initial concentration of B12b, 5 × 10−5 M; concentration of AH2, 0.05–0.25 × 10−3 M; degradation time, 15 h (pH 1–2), 3 h (pH 2.5), 1 h (pH 3.0–6.5), 3 h (pH 7.0–8.0); temperature, 25 ± 1°C; storage, in dark
a n = 3
bAH2 concentration (M × 103)
Table V.
Second-Order Rate Constants (k 2) for the Interaction of Ascorbic acid (AH2) with Cyanocobalamin (B12) and Hydroxocobalamin (B12b) at pH 1.0–8.0
| pH | k 2 [M−1 s−1] ± SDa | |
|---|---|---|
| B12 × 102 | B12b × 102 | |
| 1.0 | 0.05 ± 0.002 | 1.10 ± 0.06 |
| 1.5 | 0.06 ± 0.003 | 1.36 ± 0.05 |
| 2.0 | 0.11 ± 0.004 | 2.56 ± 0.11 |
| 2.5 | 0.15 ± 0.008 | 4.20 ± 0.19 |
| 3.0 | 0.19 ± 0.007 | 9.20 ± 0.51 |
| 3.5 | 0.22 ± 0.009 | 17.88 ± 0.72 |
| 4.0 | 0.25 ± 0.012 | 26.60 ± 0.99 |
| 4.5 | 0.27 ± 0.014 | 29.02 ± 0.99 |
| 5.0 | 0.28 ± 0.013 | 30.08 ± 1.20 |
| 5.5 | 0.27 ± 0.015 | 27.20 ± 1.09 |
| 6.0 | 0.24 ± 0.009 | 16.81 ± 0.67 |
| 6.5 | 0.16 ± 0.008 | 13.80 ± 0.65 |
| 7.0 | 0.10 ± 0.006 | 11.04 ± 0.49 |
| 7.5 | 0.06 ± 0.002 | 8.08 ± 0.34 |
| 8.0 | 0.05 ± 0.002 | 6.40 ± 0.29 |
Experimental conditions were as follows: initial concentration of B12 and B12b, 5 × 10−5 M; concentration of AH2, 0.25–1.5 × 10−3 M (B12) and 0.05–0.25 × 10−3 M (B12b); degradation time, 1–15 h; temperature, 25 ± 1°C; storage, in dark
a n = 3
Effect of pH
The pH has a significant effect on the degradation of both B12 and B12b in the presence of AH2. The rate–pH profiles give an indication of the interactions between drugs and the rate at which different ionic/non-ionic species undergo degradation as a function of pH. These profiles are helpful in the prediction of the pH of maximum stability of drug substances for the formulation of liquid preparations (38,47). The k2versus pH profiles for the degradation of B12 and B12b in the presence of AH2 are shown in Figs. 3 and 4, respectively. Both profiles are bell-shaped with maxima around pH 5.0. Such profiles imply acid/base dissociation in the reactants. This is possible in the case of AH2 (pKa, 4.17) (44) whose monoanion AH− is the reactive species and its concentration would determine the rate of interaction between AH2 and B12 or B12b. As the reaction of AH2 species (AH2 and AH−) with B12 and B12b proceeds, the formation of AH− anions is increased with pH and hence the rate of interaction between AH2 and B12 or B12b, reaching a maximum around pH 5.0. A decrease in pH from 5.0 to 1.0 leads to an increase in the nonionic species of AH2 and thus the resultant decrease in the rate of interaction. Moreover, the protonated form of B12 (pKa 3.3) (48) may be less susceptible to degradation than the neutral form. An increase in pH tends to destroy the AH− anions by oxidation (49), resulting in a gradual decrease in the rate of interaction between AH2 and B12/B12b. A similar rate–pH profile for the degradation of B12b in the presence of formate anions (pHmax 5.5) has been reported (50), indicating a similarity of the reaction between ascorbate and formate anions as reductants of B12 and B12b, respectively.
Fig. 3.

k 2–pH profile for the degradation of cyanocobalamin (B12) at pH 1–8
Fig. 4.

k 2–pH profile for the degradation of hydroxocobalamin (B12b) at pH 1–8
Effect of Buffer
The buffer salts normally used to maintain the pH of pharmaceutical preparations may lead to the degradation of drug substances by acid-base catalysis (38,47). Phosphate salts are commonly used as buffers in the pH range 6.0–8.0 and have been found to catalyze the degradation of drugs including phenytoin (51), codeine (52), ciclosidomine (53), spironolactone (54), gonadorelin (55), riboflavin (56–59), and formylmethylflavin (60). Since the degradation of B12 in this study has also been carried out in phosphate buffer (pH 6.0–8.0), it was considered necessary to evaluate the catalytic effect of phosphate species on the degradation of B12 in 0.02–0.10 M phosphate buffer in the presence of 1.5 × 10−3 M AH2. The graphs of kobsversus phosphate concentration are linear with a negative slope (R2 = 0.997–0.999) and the second-order rate constants (k2) for the degradation of B12 in the presence of phosphate species at pH 6.0, 7.0, and 8.0 obtained from the slopes of the plots are 1.04, 0.40, and 0.21 × 10−4 M−1 s−1, respectively. The values of apparent first-order rate constants, ko, at zero buffer concentration at pH 6.0, 7.0, and 8.0 obtained from y-intercepts of the second-order plots are 1.74, 0.63, and 0.26 × 10−5 s−1, indicating the inhibitory effect of phosphate species on the reaction. The decrease in the values of k2, with pH, suggests that the monovalent phosphate species (H2PO4−) (pKa 7.21) are more effective than the divalent phosphate species (HPO42−) in causing the catalytic degradation of AH2 which would in turn have a lower effect on the degradation of B12.
In the present work, the degradation studies on B12 and B12b have been carried out in the presence of AH2 and the values of pHmax obtained are around pH 5.0 (Figs. 3 and 4). Since the phosphate species present in the buffer system (pH 6.0–8.0) are also catalytic to ascorbate monoanion (AH−) in the pH range 5.85–7.22 (61), there is a possibility that the buffer species may catalyze the oxidation of AH− anions thereby inhibiting their effect on the degradation of B12 and B12b. This has in fact been confirmed by conducting the B12 degradation reactions in phosphate buffer. It is evident that the rates of B12 and B12b degradation increase with a decrease in buffer concentration due to the presence of a relatively greater amount of AH− anions which would interact with these vitamins. Phosphate species tend to destroy AH− anions above pH 5.0, and their rate of oxidation is minimum at pH 5.6 (62) which is slightly above the pHmax for B12 and B12b. The greater stability and reactivity of AH2 at pH 5.0 compared to that of pH 7.0 is due to its lower redox potential at pH 5.0 (E° = −0.117 V) than that at pH 7.0 (E° = +0.058 V) (63). The decrease in the rate of degradation of these vitamins above pH 5.0 (Figs. 3 and 4) is probably due to a gradual decrease in the availability of AH− anions for interaction with B12 and B12b.
Distribution of Degradation Products of B12
The present study has shown that the degradation of B12 in the presence of AH2 leads to the formation of B12b and the oxidation products (OP) at pH 1.0–8.0. The product distribution at 50% degradation of B12 along with the t1/2 values of B12 and B12b are given in Table VI. A comparison of the molar concentrations of B12b and OP at various pH values shows that the ratios of OP to B12b decrease with pH from 1.81 (pH 1.0) to 0.10 (pH 8.0). This could be due to the simultaneous oxidation of AH2/AH− species with an increase in pH and thus being less effective in causing the oxidation of B12b. The greater stability of B12 at pH 1.0–2.0 (97–99% protonated form) (pKa 3.5) (48) indicates that the protonated form of B12 (B12 H+) is resistant to degradation. The values of OP at pH 1.0–2.0 may include certain amount of B12r which would also be more stable to oxidation in this pH range. The relatively high values of OP and the greater stability of B12b at pH 1.0–2.0 suggest that these may have a contribution from B12r. The t1/2 values for B12 and B12b in the pH range indicate that B12 is more stable to degradation than B12b as reported in the earlier studies (28,32,46).
Table VI.
Product distribution at 50% degradation (t 1/2) of cyanocobalamin (B12) solutions at pH 1.0–8.0
| pH | t 1/2 (h) | B12 (M × 105) | B12b (M × 105) | OPa (M × 105) | OP/B12b |
|---|---|---|---|---|---|
| 1.0 | 137.50 (87.50)b | 2.50 | 0.89 | 1.61 | 1.81 |
| 2.0 | 74.03 (30.08)b | 2.50 | 1.26 | 1.24 | 0.98 |
| 3.0 | 26.74 (8.37)b | 2.50 | 2.05 | 0.45 | 0.22 |
| 4.0 | 14.58 (2.89)b | 2.50 | 2.09 | 0.41 | 0.19 |
| 5.0 | 13.75 (2.53)b | 2.50 | 2.14 | 0.36 | 0.17 |
| 6.0 | 15.78 (4.58)b | 2.50 | 2.20 | 0.30 | 0.14 |
| 7.0 | 44.77 (6.97)b | 2.50 | 2.24 | 0.26 | 0.12 |
| 8.0 | 120.31 (12.03)b | 2.50 | 2.29 | 0.22 | 0.10 |
Experimental conditions were as follows: initial concentration of B12 and B12b, 5 × 10−5 M; concentration of AH2, 1.50 × 10−3 M (B12), 0.025 × 10−3 M (B12b); degradation time, 15 h; temperature, 25 ± 1°C; storage, in dark
aOxidation products (OP) of B12 = [initial molar concentration of B12 – (molar concentration of B12 + molar concentration of B12b at 50% degradation)]
bThe values in parenthesis are t 1/2 of B12b
Mode of Degradation
It is well known that B12 is incompatible with reducing agents such as AH2 and is degraded in its presence at room temperature. B12b is very unstable in the presence of AH2 and is destroyed by the release of Co atom with subsequent disappearance of the color (12,24,28,29). These changes result in the cleavage of the corrin ring to form the oxidation products (9,12,28). The degradation of B12 by H2O2 (64) and HOCl (65) also results in the discoloration of the solutions and the formation of the oxidation products. In the light of the previous studies and on the basis of the present findings, schemes for the mode of degradation of B12 and B12 in the presence of AH2 are presented.
Degradation of B12
The degradation of B12 by AH2 in the pH range 1–8 proceeds slowly with AH2 species (pKa1, 4.17) (44) up to around pH 3 (3) and then with an enhancement in the rate up to pH 5 due to the participation of the AH− anions (4). This is followed by a decline in the rate of reaction due to the loss of AH− anions. This process leads to the formation of reduced B12 (B12r) by one electron transfer depending upon the pH and the redox potential of the B12/B12r system (E° pH 7.0 = −0.04 V) (66). B12r is directly oxidized to form B12b by the replacement of CN− by an OH− group (5). Alternatively, it could undergo cleavage of the corrin ring to produce colorless oxidation products (6). The (5) and (6) reactions may occur simultaneously under the conditions employed. B12r can also disproportionate to B12s (Co(I)alamin) and B12b (7) (13). Thus, B12b could be generated by more than one pathway ((5) and (7)), whereas OP are formed through B12b only. This would result in a gradual decrease in the OP/B12b ratios as observed in the present study (Table II). These reactions are presented in Scheme 1:
![]() |
3 |
![]() |
4 |
![]() |
5 |
![]() |
6 |
![]() |
7 |
Degradation of B12b
The degradation of B12b by AH2/AH− species (8) follows the same pattern as observed for B12, resulting in the formation of the reduced B12b (B12br) (9). Similar to the reactions of B12 given in Scheme 1, B12br may be oxidized to B12b (10) or may undergo cleavage of the corrin ring to yield the oxidation products (11). The formation of the oxidation products may depend on the pH and the rate of interaction of AH− anions with the B12b. The degradation reactions of B12b are presented in Scheme 2:
![]() |
8 |
![]() |
9 |
![]() |
10 |
![]() |
11 |
CONCLUSION
Cyanocobalamin (B12) and hydroxocobalamin (B12b) both degrade in the dark by first-order kinetics in the presence of ascorbic acid (AH2) at pH 1.0–8.0. A comparison of the kinetic data shows that the degradation of B12b is much faster than that of B12. The maximum rate of degradation of B12 and B12b occurs at pH 5.0, indicating the highest rate of interaction of AH2 with B12 and B12b at that pH. The protonated forms of B12 and B12b are less susceptible to degradation as evident from the values of the rate constants at pH 1–3. The enhancement in the rate of reaction in the pH range 1–5 is due to gradual ionization of AH2 to form the ascorbate monoanion (AH−) and the reduction in the rate above pH 5 is a result of the loss of AH− anions by oxidation. The degradation of B12 and B12b involves the reduction of Co3+ to Co2+ in the corrin ring by AH2, followed by the oxidation to B12b and/or the ring cleavage products. These reactions would depend on the pH, concentration of AH2 and the redox potential of the Co3+/Co2+ system.
References
- 1.Smith EL. Purification of anti-pernicious anemia factors from liver. Nature. 1948;161:638. doi: 10.1038/161638a0. [DOI] [PubMed] [Google Scholar]
- 2.Rickes EL, Brink NG, Koniuszy FR, Wood TR, Folkers K. Crystalline vitamin B12. Science. 1948;107:396–7. doi: 10.1126/science.107.2781.396. [DOI] [PubMed] [Google Scholar]
- 3.Banerjee R, Ragsdale SW. The many faces of vitamin B12: catalysis by cobalamin-dependent enzymes. Annu Rev Biochem. 2003;72:209–47. doi: 10.1146/annurev.biochem.72.121801.161828. [DOI] [PubMed] [Google Scholar]
- 4.Green R, Miller JW. Vitamin B12. In: Zempleni J, Rucker RB, McCormick DB, Suttie JW, editors. Handbook of vitamins. 4. Boca Raton: CRC Press; 2007. pp. 413–57. [Google Scholar]
- 5.British Pharmacopoeia, 2013. Monographs on cyanocobalamin and hydroxocobalamin. London, UK: Her Majesty’s Stationary Office, Electronic version; 2013.
- 6.Baxter N, Horsford J, Wokes F, Norris FW, Fernandes SJG. Cyanocobalamin and hydroxocobalamin in vitamer B12 injections. J Pharm Pharmacol. 1953;5:723–36. doi: 10.1111/j.2042-7158.1953.tb14038.x. [DOI] [PubMed] [Google Scholar]
- 7.Hayward GC, Hill HAO, Pratt JM, Vanston NJ, Williams RJP. The chemistry of vitamin B12. Part IV. The thermodynamic trans-effect. J Chem Soc. 1965;6485–93. [PubMed]
- 8.Vogler A, Hirschmann R, Otto H, Kunkely H. Photochemistry of biologically important transition metal complexes. I. Cyanocobalamin and related corrin complexes of rhodium(III) Ber Bunsenges Physik Chem. 1976;80:420–4. doi: 10.1002/bbpc.19760800506. [DOI] [Google Scholar]
- 9.Connors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals a handbook for pharmacists. 2. New York: John Willey; 1986. pp. 377–84. [Google Scholar]
- 10.Ahmad I, Hussain W, Fareedi AA. Photolysis of cyanocobalamin in aqueous solution. J Pharm Biomed Anal. 1992;10:9–15. doi: 10.1016/0731-7085(92)80004-7. [DOI] [PubMed] [Google Scholar]
- 11.Ahmad I, Hussain W. Stability of cyanocobalamin solutions in sunlight and artificial light. Pak J Pharm Sci. 1993;6:23–8. [PubMed] [Google Scholar]
- 12.Macek TJ. Stability problems with some vitamins in pharmaceuticals. Am J Pharm. 1960;132:433–55. [PubMed] [Google Scholar]
- 13.Kirschbaum J. Cyanocobalamin. In: Florey K, editor. Analytical profiles of drug substances. New York: Academic; 1981. pp. 183–288. [Google Scholar]
- 14.DeRitter E. Vitamins in pharmaceutical formulations. J Pharm Sci. 1982;71:1073–96. doi: 10.1002/jps.2600711003. [DOI] [PubMed] [Google Scholar]
- 15.Heathcote J, Wills BA. Hydrolytic destruction of thiamine, especially in the presence of cyanocobalamin. J Pharm Pharmacol. 1962;14:232–6. doi: 10.1111/j.2042-7158.1962.tb11084.x. [DOI] [PubMed] [Google Scholar]
- 16.Doerge RF, Ravin LJ, Caldwell HC. Effect of the thiazole moiety of thiamine hydrochloride and selected model compounds on cyanocobalamin stability. J Pharm Sci. 1965;54:1038–41. doi: 10.1002/jps.2600540719. [DOI] [PubMed] [Google Scholar]
- 17.Mukherjee SL, Sen SP. Stability of vitamin B12. Part II. Protection by an iron salt against destruction by aneurine and nicotinamide. J Pharm Pharmacol. 1959;11:26–31. doi: 10.1111/j.2042-7158.1959.tb12520.x. [DOI] [PubMed] [Google Scholar]
- 18.Ahmad I, Ansari IA, Ismail T. Effect of nicotinamide on the photolysis of cyanocobalamin in aqueous solution. J Pharm Biomed Anal. 2003;31:369–74. doi: 10.1016/S0731-7085(02)00337-0. [DOI] [PubMed] [Google Scholar]
- 19.Ahmad I, Hussain W. Multicomponent spectrophotometric assay of cyanocobalamin, hydroxocobalamin and riboflavin. Pak J Pharm Sci. 1992;5:121–7. [PubMed] [Google Scholar]
- 20.Ahmad I, Hafeez A, Akhter N, Vaid FHM, Qadeer K. Effect of riboflavin on the photolysis of cyanocobalamin in aqueous solution. Open Anal Chem J. 2012;6:22–7. doi: 10.2174/1874065001206010022. [DOI] [Google Scholar]
- 21.Juzeniene A, Nizauskaite Z. Photodegradation of cobalamins in aqueous solutions and in human blood. J Photochem Photobiol B Biol. 2013;122:7–14. doi: 10.1016/j.jphotobiol.2013.03.001. [DOI] [PubMed] [Google Scholar]
- 22.Ansari A, Vaid FHM, Ahmad I. Spectral study of photolysis of aqueous cyanocobalamin solutions in presence of vitamins B and C. Pak J Pharm Sci. 2004;17:93–9. [PubMed] [Google Scholar]
- 23.Ichikawa M, Ide N, Shiraishi S, Ono K. Effect of various halide salts on the incompatibility of cyanocobalamin and ascorbic acid in aqueous solution. Chem Pharm Bull. 2005;53:688–90. doi: 10.1248/cpb.53.688. [DOI] [PubMed] [Google Scholar]
- 24.Frost DV, Lapidus M, Plaut KA, Scherfling E, Fricke HH. Differential stability of various analogs of cobalamin to vitamin C. Science. 1952;116:119–21. doi: 10.1126/science.116.3005.119. [DOI] [PubMed] [Google Scholar]
- 25.Marcus M, Prabhudesai M, Wassef S. Stability of vitamin B12 in the presence of ascorbic acid in food and serum: restoration by cyanide of apparent loss. Am J Clin Nutr. 1980;33:137–43. doi: 10.1093/ajcn/33.1.137. [DOI] [PubMed] [Google Scholar]
- 26.Newmark HL, Scheiner MS, Marcus M, Prabhudesai M. Stability of vitamin B12 in the presence of ascorbic acid. Am J Clin Nutr. 1976;29:645–9. doi: 10.1093/ajcn/29.6.645. [DOI] [PubMed] [Google Scholar]
- 27.Herbert V, Jacob E. Destruction of vitamin B by ascorbic acid. JAMA. 1974;230:241–2. doi: 10.1001/jama.1974.03240020031018. [DOI] [PubMed] [Google Scholar]
- 28.Trenner NR, Buhs RP, Bacher FA, Gakenheimer WC. A note concerning the incompatibility of vitamin B12 and ascorbic acid. J Am Pharm Assoc. 1950;39:361. doi: 10.1002/jps.3030390619. [DOI] [PubMed] [Google Scholar]
- 29.Campbell JA, McLaughlan JM, Chapman DG. A method for the differentiation of hydroxocobalamin from cyanocobalamin employing the ascorbic acid reaction. J Am Pharm Assoc. 1952;41:479–81. doi: 10.1002/jps.3030410907. [DOI] [PubMed] [Google Scholar]
- 30.Hutchins HH, Cravioto PJ, Macek TJ. A comparison of the stability of cyanocobalamin and its analogs in ascorbate solution. J Am Pharm Assoc. 1956;45:806–8. doi: 10.1002/jps.3030451211. [DOI] [PubMed] [Google Scholar]
- 31.Ahmad I, Hussain W. Stability of cyanocobalamin in parenteral preparations. Pak J Pharm Sci. 1993;6:53–9. [PubMed] [Google Scholar]
- 32.Hogenkamp HPC. The interaction between vitamin B12 and vitamin C. Am J Clin Nutr. 1980;33:1–3. doi: 10.1093/ajcn/33.1.1. [DOI] [PubMed] [Google Scholar]
- 33.Kuehl FA, Jr, Shunk CH, Moore M, Folkers K. Vitamin B12. XXV. 3,3-Dimethyl-2,5-dioxopyrrolidine-4-propionamide: a new degradation product. J Am Chem Soc. 1955;77:4418–9. doi: 10.1021/ja01621a075. [DOI] [Google Scholar]
- 34.Marcus AD, Stanley JL. Stability of the cobalamin moiety in buffered aqueous solutions of hydroxocobalamin. J Pharm Sci. 1964;53:91–4. doi: 10.1002/jps.2600530118. [DOI] [PubMed] [Google Scholar]
- 35.Zuck DA, Conine JW. Stabilization of vitamin B12 I. Complex cyanides. J Pharm Sci. 1963;52:59–63. doi: 10.1002/jps.2600520112. [DOI] [PubMed] [Google Scholar]
- 36.Conine JW, Zuck DA. Stabilization of vitamin B12. II. Alpha-Hydroxynitriles. J Pharm Sci. 1963;52:63–6. doi: 10.1002/jps.2600520113. [DOI] [PubMed] [Google Scholar]
- 37.Pratt JM. The chemistry of vitamin B12. Part II. Photochemical reactions. J Chem Soc. 1964;5154–60.
- 38.Sinko PJ. Martin’s physical pharmacy and pharmaceutical sciences. 5. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 205–6. [Google Scholar]
- 39.Cima L, Mantovan R. Cyanocobalamin and hydroxocobalamin separation by thin-layer chromatography. Farmaco Ed Prat. 1962;17:473–81. [Google Scholar]
- 40.Covello M, Schettino O. Determination by chromatospectrophotometry of hydroxo- and cyanocobalamin combined with other medicaments in various pharmaceutical forms. Farmaco Ed Prat. 1964;19:38–51. [PubMed] [Google Scholar]
- 41.Ganshirt H, Malzacher A. Separation of several vitamins of the B group and C by chromatography. Naturwiss. 1960;47:279–80. doi: 10.1007/BF01210760. [DOI] [Google Scholar]
- 42.Bolliger HR, Konig A. Water-soluble vitamins. In: Stahl E, editor. Thin-layer chromatography. Berlin: Springer; 1969. pp. 304–6. [Google Scholar]
- 43.Moffat C, Osselton MD, Widdop B. Clark’s analysis of drugs and poisons. 4th ed. London, UK: Pharmaceutical Press; 2011. p. 1173, 1500.
- 44.O’Neil MJ. The merck index, 15th ed. Cambridge, UK: The Royal Society of Chemistry; 2013. Electronic version.
- 45.Lexa D, Saveant JM, Zickler J. Electrochemistry of vitamin B12. 5. Cyanocobalamins. J Am Chem Soc. 1980;102:2654–63. doi: 10.1021/ja00528a023. [DOI] [Google Scholar]
- 46.Loy HW, Haggerty JF, Kline OL. Stability of vitamin B12 and B12b. J Assoc Offic Agr Chemists. 1952;35:169–74. [Google Scholar]
- 47.Carstensen JT. Kinetic pH profiles. In: Carstensen JT, Rhodes CT, editors. Drug stability principles and practices. 3. New York: Marcel Dekker; 2000. pp. 57–111. [Google Scholar]
- 48.Hill HAO, Pratt JM, Williams RJP. The corphyrins. J Theor Biol. 1962;3:423–5. doi: 10.1016/S0022-5193(62)80035-6. [DOI] [Google Scholar]
- 49.Allwood MC, Kearney MC. Compatibility and stability of additives in parenteral nutrition admixtures. Nutrition. 1998;14:697–706. doi: 10.1016/S0899-9007(98)00063-X. [DOI] [PubMed] [Google Scholar]
- 50.Linn DE, Jr, Gould ES. Electron transfer. 92. Reductions of vitamin B12a (hydroxocobalamin) with formate and related formyl species. Inorg Chem. 1988;27:1625–8. doi: 10.1021/ic00282a023. [DOI] [Google Scholar]
- 51.Varia SA, Schuller S, Stella VJ. Phenytoin prodrugs IV: hydrolysis of various 3-(hydroxymethyl)phenytoin esters. J Pharm Sci. 1984;73:1074–80. doi: 10.1002/jps.2600730813. [DOI] [PubMed] [Google Scholar]
- 52.Powell MF. Enhanced stability of codeine sulfate: effect of pH, buffer, and temperature on the degradation of codeine in aqueous solution. J Pharm Sci. 1986;75:901–3. doi: 10.1002/jps.2600750917. [DOI] [PubMed] [Google Scholar]
- 53.Carney CF. Solution stability of ciclosidomine. J Pharm Sci. 1987;76:393–7. doi: 10.1002/jps.2600760511. [DOI] [PubMed] [Google Scholar]
- 54.Pramar Y, Gupta VD. Preformulation studies of spironolactone: effect of pH, two buffer species, ionic strength, and temperature on stability. J Pharm Sci. 1991;80:551–3. doi: 10.1002/jps.2600800611. [DOI] [PubMed] [Google Scholar]
- 55.Hoitink MA, Beijnen JH, Bult A, van der Houwen OAGJ, Nijholt J, Underberg WJM. Degradation kinetics of gonadorelin in aqueous solution. J Pharm Sci. 1996;85:1053–9. doi: 10.1021/js9601187. [DOI] [PubMed] [Google Scholar]
- 56.Ahmad I, Fasihullah Q, Vaid FHM. A study of simultaneous photolysis and photoaddition reactions of riboflavin in aqueous solution. J Photochem Photobiol B Biol. 2004;75:13–20. doi: 10.1016/j.jphotobiol.2004.04.001. [DOI] [PubMed] [Google Scholar]
- 57.Ahmad I, Fasihullah Q, Vaid FHM. Effect of phosphate buffer on photodegradation reactions of riboflavin in aqueous solution. J Photochem Photobiol B Biol. 2005;78:229–34. doi: 10.1016/j.jphotobiol.2004.11.010. [DOI] [PubMed] [Google Scholar]
- 58.Ahmad I, Fasihullah Q, Vaid FHM. Effect of light intensity and wavelengths on photodegradation reactions of riboflavin in aqueous solution. J Photochem Photobiol B Biol. 2006;82:21–7. doi: 10.1016/j.jphotobiol.2005.08.004. [DOI] [PubMed] [Google Scholar]
- 59.Ahmad I, Ahmed S, Sheraz MA, Vaid FHM, Ansari IA. Effect of divalent anions on photodegradation kinetics and pathways of riboflavin in aqueous solution. Int J Pharm. 2010;390:174–82. doi: 10.1016/j.ijpharm.2010.01.042. [DOI] [PubMed] [Google Scholar]
- 60.Ahmad I, Mirza T, Iqbal K, Ahmed S, Sheraz MA, Vaid FHM. Effect of pH, buffer and viscosity on the photolysis of formylmethylflavin: a kinetic study. Aust J Chem. 2013;66:579–85. [Google Scholar]
- 61.Blaug SM, Hajratwala B. Kinetics of aerobic oxidation of ascorbic acid. J Pharm Sci. 1972;61:556–62. doi: 10.1002/jps.2600610412. [DOI] [PubMed] [Google Scholar]
- 62.Rogers AR, Yacomeni JA. The effect of pH on the aerobic degradation of ascorbic acid solutions. J Pharm Pharmcol. 1971;23:218S. doi: 10.1111/j.2042-7158.1971.tb08797.x. [DOI] [PubMed] [Google Scholar]
- 63.Fasman GD. CRC handbook of biochemistry and molecular biology. 3. Boca Raton: CRC Press; 1976. p. 122. [Google Scholar]
- 64.Beiler JM, Moss JN, Martin GJ. Formation of a competitive antagonist of vitamin B12 by oxidation. Science. 1951;114:122–3. doi: 10.1126/science.114.2953.122-a. [DOI] [PubMed] [Google Scholar]
- 65.Abu-Soud HM, Maitra D, Byun J, Souza CE, Banerjee J, Saed GM, et al. The reaction of HOCl and cyanocobalamin: corrin destruction and the liberation of cyanogen chloride. Free Radic Biol Med. 2012;52:616–25. doi: 10.1016/j.freeradbiomed.2011.10.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Lexa D, Saveant JM, Zickler J. Electrochemistry of vitamin B12. 2. Redox and acid-base equilibria in the B12a/B12r system. J Am Chem Soc. 1977;99:2786–90. doi: 10.1021/ja00450a061. [DOI] [PubMed] [Google Scholar]











